Meeting
2017 ASCO Annual Meeting
A pilot trial of irinotecan, temozolomide and bevacizumab (ITB) for treatment of newly diagnosed patients with desmoplastic small round cell tumor (DSRCT).
Authors
Heather D. Magnan
Memorial Sloan Kettering Cancer Center, New York, NY
Heather D. Magnan , Anita Price , Alexander J. Chou , Elyn Riedel , Leonard H. Wexler , Srikanth R. Ambati , Emily Kanaya Slotkin , Gary Ulaner , Shakeel Modak , Michael P. La Quaglia , Paul A. Meyers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01189643
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11050)
DOI
10.1200/JCO.2017.35.15_suppl.11050
Abstract #
11050
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2023 ASCO Annual Meeting
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
First Author: Luciana Vinti
Poster
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
First Author: Jane N. Winter